We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $57 · 8 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors. - The Motley Fool
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors. The Motley Fool
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
Number of shareholders of Enliven Therapeutics, Inc. – NASDAQ:ELVN - TradingView
Number of shareholders of Enliven Therapeutics, Inc. – NASDAQ:ELVN TradingView
ELVN: Advancing a selective CML therapy with strong efficacy, safety, and pivotal trials planned - TradingView
ELVN: Advancing a selective CML therapy with strong efficacy, safety, and pivotal trials planned TradingView
Assessing Enliven Therapeutics (ELVN) Valuation After A Strong Year-To-Date Share Price Surge - simplywall.st
Assessing Enliven Therapeutics (ELVN) Valuation After A Strong Year-To-Date Share Price Surge simplywall.st
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 13. | After market close (AMC) | $-0.4 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 09. | Goldman Sachs | — | Maintain | Buy → Buy | — | Goldman Sachs: Buy |
| 2026. 03. 26. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,504,601 | $23.17B | 0.04% | — | New position |
See new positions, full exits, and weight changes.